ArticleCancers2016
Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.
Article in Cancers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer.Journal of geriatric oncology · 2021Trial
- Older Adult Participation in Early-Phase Lung Cancer Clinical Trials, 1998 to 2020.JTO clinical and research reports · 2025Article
- Targeting Aging Hallmarks with Monoclonal Antibodies: A New Era in Cancer Immunotherapy and Geriatric Medicine.International journal of molecular sciences · 2025Review
- Effect of repeated bolus and continuous doxorubicin administration on bone and soft tissue concentrations- a randomized study evaluated in a tumour-free porcine model.Cancer chemotherapy and pharmacology · 2025Article
- Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review.Clinical pharmacokinetics · 2025Review
- A Population Pharmacokinetic Study to Evaluate Doxorubicin Exposure Across All Age Groups.Clinical pharmacokinetics · 2024Article
- Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway.Journal of translational medicine · 2024Review
- Key Considerations for the Treatment of Advanced Breast Cancer in Older Adults: An Expert Consensus of the Canadian Treatment Landscape.Current oncology (Toronto, Ont.) · 2023Review
- Life-Threatening Hematoma in an Elderly Breast Cancer Patient Undergoing Chemotherapy.Journal of breast cancer · 2023Article
- Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer: a pilot study.Cancer chemotherapy and pharmacology · 2023Article
- The clinical features, management, and survival of elderly patients with gastric cancer.Journal of gastrointestinal oncology · 2022Article
- Utilisation of Adjuvant Chemotherapy and 5-Year Survival Analysis of Prospectively Recorded Cohort Data for Older Adults Versus Younger Adults with Resected Primary Colon Cancer.Journal of gastrointestinal cancer · 2020Article
- Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper.Blood advances · 2020Review
- Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study.Pharmaceutical research · 2019Article
- Modeling individual time courses of thrombopoiesis during multi-cyclic chemotherapy.PLoS computational biology · 2019Article
- Article
- Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.Breast cancer (Tokyo, Japan) · 2018Article
- Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.Investigational new drugs · 2017Observational
- Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update.International journal of molecular sciences · 2017Review
- Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.Journal of gastrointestinal cancer · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundElderly patients receiving anticancer drugs may have an increased risk to develop treatment-related toxicities compared to their younger peers. However, a potential pharmacokinetic (PK) basis for this increased risk has not consistently been established yet. Therefore, the objective of this study was to systematically review the influence of age on the PK of anticancer agents frequently administered to elderly breast cancer patients.
methodsA literature search was performed using the PubMed electronic database, Summary of Product Characteristics (SmPC) and available drug approval reviews, as published by EMA and FDA. Publications that describe age-related PK profiles of selected anticancer drugs against breast cancer, excluding endocrine compounds, were selected and included.
resultsThis review presents an overview of the available data that describe the influence of increasing age on the PK of selected anticancer drugs used for the treatment of breast cancer.
conclusionsSelected published data revealed differences in the effect and magnitude of increasing age on the PK of several anticancer drugs. There may be clinically-relevant, age-related PK differences for anthracyclines and platina agents. In the majority of cases, age is not a good surrogate marker for anticancer drug PK, and the physiological state of the individual patient may better be approached by looking at organ function, Charlson Comorbidity Score or geriatric functional assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.